Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 20

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
Accumulated other comprehensive loss(402,826)(428,809)Accumulated deficit(183,684,420)(175,289,630)Total stockholders' deficit(12,733,260)(6,012,089)Total liabilities and stockholders' deficit$12,979,525 $22,101,131 

See accompanying notes.

1

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Three months ended June 30,Six months ended June 30,2025202420252024RevenueRoyalty revenue$(21,172)$22,438 $4,255 $31,740 Total revenue(21,172)22,438 4,255 31,740 Operating expensesGeneral and administrative2,377,866 2,448,130 4,687,030 5,118,711 Research and development1,428,762 4,933,774 3,726,143 8,287,294 Royalty expense— — — 7,674 Total operating expenses3,806,628 7,381,904 8,413,173 13,413,679 Loss from operations(3,827,800)(7,359,466)(8,408,918)(13,381,939)Other income (expense)Sale of royalty and milestone rights, net— 20,379,376 — 20,379,376 Other income (expense), net(188,683)(109,254)14,128 (842,137)Net income (loss)$(4,016,483)$12,910,656 $(8,394,790)$6,155,300 Foreign currency translation adjustments12,893 14,563 25,983 (24,664)Comprehensive income (loss)$(4,003,590)$12,925,219 $(8,368,807)$6,130,636 Income (loss) per common share:Basic$(0.45)$1.53 $(0.95)$0.73 Diluted$(0.45)$1.52 $(0.95)$0.72 Weighted average number of shares outstanding:Basic8,871,155 8,411,242 8,815,414 8,456,270 D